Atai Life Sciences – Talk Bio

Actionable Insights Powered by AI

Atai’s Schizophrenia Drug Fails to Improve Cognition in Phase 2 Study

4 weeks ago talkbio0Tagged Atai Life Sciences, CIAS, clinical endpoints, Clinical trial failure, Cognition, Impaired cognition, inidascamine, Recognify Life Sciences, Schizophrenia

Atai Life Sciences; Recognify Life Sciences; inidascamine; schizophrenia; cognitive impairment; Phase 2b trial; clinical trial failure; cognition; CIAS; clinical endpoints